Accuray Management

Management criteria checks 1/4

Accuray's CEO is Suzanne Winter, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is $2.64M, comprised of 24.8% salary and 75.2% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $1.02M. The average tenure of the management team and the board of directors is 1.9 years and 3.5 years respectively.

Key information

Suzanne Winter

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage	24.8%
CEO tenure	2.8yrs
CEO ownership	0.5%
Management average tenure	1.9yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Suzanne Winter's remuneration changed compared to Accuray's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$15m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	US$3m	US$653k	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	n/a	n/a	-US$12m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	US$2m	US$543k	-US$5m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	n/a	n/a	-US$12m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	US$2m	US$417k	-US$6m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	n/a	n/a	US$8m
Sep 30 2020	n/a	n/a	US$14m
Jun 30 2020	US$2m	US$311k	US$4m

Compensation vs Market: Suzanne's total compensation ($USD2.64M) is above average for companies of similar size in the UK market ($USD759.50K).

Compensation vs Earnings: Suzanne's compensation has increased whilst the company is unprofitable.

CEO

Suzanne Winter (60 yo)

2.8yrs

Tenure

US$2,635,689

Compensation

Ms. Suzanne Winter, M.B.A., serves as the Director at Accuray Incorporated since April 27, 2022 and as its Chief Executive Officer since July 1, 2022. Also serve as the President at Accuray Incorporated si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Suzanne Winter	President	2.8yrs	US$2.64m	0.47% $ 1.0m
Ali Pervaiz	Senior VP & CFO	1.9yrs	US$1.09m	0.26% $ 565.3k
Michael Hoge	Senior Vice President of Global Operations	4.2yrs	US$1.02m	0.39% $ 866.3k
Jesse Chew	Senior VP	5.5yrs	US$1.11m	0.15% $ 323.6k
Sandeep Chalke	Senior VP & Chief Commercial Officer	1.9yrs	US$1.35m	0.086% $ 188.7k
Gina Corradetti	VP, Chief Accounting Officer	1.3yrs	no data	0.15% $ 319.4k
John Dunn	Vice President	no data	no data	no data
Beth Kaplan	Public Relations Director	9.8yrs	no data	no data
Melanie Gebauer	Vice President of Global Human Resources	1.4yrs	no data	no data
Juki Hozumi	President & GM of Japan Region	1.4yrs	no data	no data
Scott Chapman	Senior Vice President of Global Service	less than a year	no data	no data
Jim Dennison	Senior Vice President of Global Regulatory	3.4yrs	no data	no data

1.9yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 0H8I's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Suzanne Winter	President	2yrs	US$2.64m	0.47% $ 1.0m
Joseph Whitters	Independent Chairman of the Board	5.8yrs	US$245.52k	0.41% $ 897.9k
James Hindman	Independent Director	4.6yrs	US$198.87k	0.18% $ 403.1k
Beverly Huss	Independent Director	6.3yrs	US$193.56k	0.15% $ 340.6k
Robert Kill	Independent Director	1.3yrs	US$134.35k	0.15% $ 332.1k
Mika Nishimura	Independent Director	2.7yrs	US$180.52k	0.10% $ 220.8k
Byron Scott	Independent Director	3.2yrs	US$186.06k	0.086% $ 189.5k
Anne Le Grand	Independent Director	3.8yrs	US$188.87k	0.15% $ 324.8k

3.5yrs

Average Tenure

61yo

Average Age

Experienced Board: 0H8I's board of directors are considered experienced (3.5 years average tenure).

Accuray Management

Management criteria checks 1/4

Key information

Recent management updates

President recently sold US$162k worth of stock

President recently sold US$99k worth of stock

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

High number of new directors

Recent updates

Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024

Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.098 loss per share (vs US$0.02 loss in 2Q 2023)

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

President recently sold US$162k worth of stock

First quarter 2024 earnings released: US$0.031 loss per share (vs US$0.058 loss in 1Q 2023)

President recently sold US$99k worth of stock

Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023

Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Forecast to breakeven in 2024

Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology

Third quarter 2023 earnings released: EPS: US$0.006 (vs US$0.011 loss in 3Q 2022)

Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A

High number of new directors

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.002 profit in 2Q 2022)

Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors

Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023

Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System

Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023

First quarter 2023 earnings released: US$0.058 loss per share (vs US$0.011 loss in 1Q 2022)

President recently sold US$76k worth of stock

Accuray Incorporated Re-Affirms Guidance for Year 2023

Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration

High number of new directors

Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia

Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022

Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

Accuray Incorporated, Annual General Meeting, Nov 10, 2022

Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated

Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer

Full year 2022 earnings released: US$0.058 loss per share (vs US$0.069 loss in FY 2021)

Accuray Incorporated Provides Revenue Guidance for Year 2023

High number of new directors

Accuray Incorporated to Report Q4, 2022 Results on Aug 10, 2022

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

Accuray Incorporated(NasdaqGS:ARAY) dropped from Russell 3000E Index

Accuray Incorporated Appoints Franco N. Palomba as Chief Accounting Officer & Controller

High number of new directors

Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer

Accuray Incorporated Announces That Clinical Studies Continue to Validate the Versatility of the Company's Cyberknife® and Tomotherapy® Platforms

High number of new directors

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.004 loss in 3Q 2021)

Accuray Incorporated Re-Affirms Earnings Guidance for the Fiscal Year 2022

Accuray Incorporated to Report Q3, 2022 Results on Apr 27, 2022

National Institute for Health and Care Excellence Endorses Radiosurgery Treatments for Trigeminal Neuralgia, Supporting Accuray Incorporated's CyberKnife System Indications for Use

Accuray Incorporated Announces Data from Phase III, Randomized Controlled Trial, TomoBreast

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022

Accuray CyberKnife Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve

President recently sold US$123k worth of stock

First quarter 2022 earnings released: US$0.011 loss per share (vs US$0.004 profit in 1Q 2021)

High number of new directors

CEO & Director recently sold US$62k worth of stock

Accuray Incorporated Announces Nagoya City University Hospital in Aichi Treats the First Cancer Patient in Japan Using the Radixact System with Clearrt Helical Fan-Beam kVCT Imaging

Accuray Cyberknife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients

Independent Chairman of the Board recently bought US$64k worth of stock

Full year 2021 earnings released: US$0.069 loss per share (vs US$0.043 profit in FY 2020)

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2022

Accuray Expands Cyberknife® System Versatility with Integration of Raysearch's Raystation Treatment Planning System

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.029 profit in 3Q 2020)